These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30581001)

  • 1. Decitabine exerted synergistic effects with oxaliplatin in colorectal cancer cells with intrinsic resistance to decitabine.
    Hosokawa M; Tanaka S; Ueda K; Iwakawa S; Ogawara KI
    Biochem Biophys Res Commun; 2019 Jan; 509(1):249-254. PubMed ID: 30581001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
    Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
    Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
    Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro.
    Abou Najem S; Khawaja G; Hodroj MH; Rizk S
    Curr Mol Pharmacol; 2019; 12(4):281-300. PubMed ID: 30868973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
    Hosokawa M; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine promotes apoptosis in mesenchymal stromal cells isolated from patients with myelodysplastic syndromes by inducing reactive oxygen species generation.
    Wang L; Guo X; Guo X; Zhang X; Ren J
    Eur J Pharmacol; 2019 Nov; 863():172676. PubMed ID: 31542488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism.
    Lin S; Lei K; Du W; Yang L; Shi H; Gao Y; Yin P; Liang X; Liu J
    Int J Biochem Cell Biol; 2016 Feb; 71():24-34. PubMed ID: 26673998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
    Chen W; Lian W; Yuan Y; Li M
    Cell Death Dis; 2019 Aug; 10(8):600. PubMed ID: 31395855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
    Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
    Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
    Huang L; Liu Z; Jiang H; Li L; Fu R
    J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer.
    Wu T; Yu Y; Tu X; Ye L; Wang J; Xie C; Kuang K; Yu Y; Zhuge W; Wang Z; Cui R; Zheng Y
    J Ethnopharmacol; 2025 Jan; 336():118754. PubMed ID: 39208999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer.
    Kim BR; Jeong YA; Jo MJ; Park SH; Na YJ; Kim JL; Jeong S; Yun HK; Kang S; Lee DH; Oh SC
    Mol Cancer Ther; 2019 Apr; 18(4):751-761. PubMed ID: 30787174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of resistance to oxaliplatin by vorinostat in human colorectal cancer cells through inhibition of Nrf2 nuclear translocation.
    Tanaka S; Hosokawa M; Tatsumi A; Asaumi S; Imai R; Ogawara KI
    Biochem Biophys Res Commun; 2022 Jun; 607():9-14. PubMed ID: 35358872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
    Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
    J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.
    Hosokawa M; Saito M; Nakano A; Iwashita S; Ishizaka A; Ueda K; Iwakawa S
    Oncol Lett; 2015 Aug; 10(2):761-767. PubMed ID: 26622566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.
    Zhang Y; Huang L; Shi H; Chen H; Tao J; Shen R; Wang T
    Cancer Sci; 2018 Jan; 109(1):94-102. PubMed ID: 29034540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
    Chen L; Wang Z; Xu Q; Liu Y; Chen L; Guo S; Wang H; Zeng K; Liu J; Zeng S; Yu L
    Theranostics; 2020; 10(8):3562-3578. PubMed ID: 32206108
    [No Abstract]   [Full Text] [Related]  

  • 19. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
    Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
    Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PGE
    Huang H; Aladelokun O; Ideta T; Giardina C; Ellis LM; Rosenberg DW
    Sci Rep; 2019 Mar; 9(1):4954. PubMed ID: 30894570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.